Evidence map›Paper›PMID 37699621›Full record

ArticleBMJ open2023

Efficacy and safety of drug therapy for the prevention and treatment of chemotherapy-induced peripheral neuropathy: a protocol for a systematic review and network meta-analysis.

Miki Takenaka Sato, Takeshi Hasegawa, Hisashi Noma, Hideki Sugita, Erika Ota

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. [Electrotherapy and sensory re-education as a treatment for chemotherapy-induced neuropathy].Revista medica del Instituto Mexicano del Seguro Social · 2026
    Trial
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Miki Takenaka SatoDepartment of Clinical Pharmacy, Showa University School of Pharmacy, Shinagawa-ku, Tokyo, Japan m-takenaka@pharm.showa-u.ac.jp.ORCID 0000-0002-0474-2007
Takeshi HasegawaShowa University Research Administration Center (SURAC), Showa University, Shinagawa-ku, Tokyo, Japan.
Hisashi NomaDepartment of Data Science, The Institute of Statistical Mathematics, Tachikawa, Tokyo, Japan.ORCID 0000-0002-2520-9949
Hideki SugitaDepartment of Hospital Pharmaceutics, Showa University School of Pharmacy, Shinagawa-ku, Tokyo, Japan.
Erika OtaGlobal Health Nursing, Graduate School of Nursing Science, St Luke's International University, Chuo-ku, Tokyo, Japan.ORCID 0000-0002-3945-7441
Showa University · JPShowa University Fujigaoka Hospital · JPSt. Luke's International University · JPThe Institute of Statistical Mathematics · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionChemotherapy-induced peripheral neuropathy (CIPN) is one of the most common dose-limiting side effects of chemotherapeutic drugs. Numerous clinical trials of various targeted drugs for the prevention or treatment of CIPN have been conducted; however, previous systematic reviews with direct comparisons have failed to demonstrate the efficacy of these drugs in the prevention or treatment of CIPN. In addition, no systematic reviews have indirectly compared CIPN prevention and treatment. This article describes a protocol for evaluating the efficacy and safety of drug therapy for the prevention and treatment of CIPN. The results of the proposed systematic review with network meta-analysis (NMA) will provide new insights into the prevention and treatment of CIPN. METHODS AND ANALYSIS: We will conduct a literature search in MEDLINE, PubMed, Embase, Cochrane Central Register of Controlled Trials and ClinicalTrials.gov to find relevant articles published through January 2023. We will include studies that investigated the efficacy and safety of vitamin B ETHICS AND DISSEMINATION: This review does not require ethical approval. The research will be published in a peer-reviewed journal. PROSPERO REGISTRATION NUMBER: CRD42022371829.

Indexed as

Antineoplastic AgentsDrug-Related Side Effects and Adverse ReactionsPeripheral Nervous System DiseasesHumansNetwork Meta-Analysis as TopicReview Literature as TopicSystematic Reviews as TopicAntineoplastic AgentsCHEMOTHERAPYNeuropathologyONCOLOGY

Identifiers

PMID37699621
PMCPMC10503317
OpenAlexW4386629686

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.